Kendall Capital Management lowered its stake in Iqvia Holdings Inc (NYSE:IQV) by 33.3% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 2,895 shares of the medical research company’s stock after selling 1,445 shares during the quarter. Kendall Capital Management’s holdings in Iqvia were worth $416,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in IQV. Oregon Public Employees Retirement Fund grew its stake in Iqvia by 44,777.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 7,140,389 shares of the medical research company’s stock valued at $61,000 after acquiring an additional 7,124,478 shares during the period. FMR LLC lifted its holdings in Iqvia by 41.1% in the 4th quarter. FMR LLC now owns 4,217,991 shares of the medical research company’s stock valued at $490,004,000 after purchasing an additional 1,228,148 shares in the last quarter. Norges Bank purchased a new position in Iqvia in the 4th quarter valued at $124,606,000. Boston Partners lifted its holdings in Iqvia by 417.6% in the 4th quarter. Boston Partners now owns 1,315,752 shares of the medical research company’s stock valued at $152,851,000 after purchasing an additional 1,061,550 shares in the last quarter. Finally, BlackRock Inc. lifted its holdings in Iqvia by 3.2% in the 4th quarter. BlackRock Inc. now owns 10,977,184 shares of the medical research company’s stock valued at $1,275,219,000 after purchasing an additional 342,256 shares in the last quarter. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

IQV has been the topic of a number of research reports. Barclays restated a “buy” rating and issued a $155.00 price objective on shares of Iqvia in a report on Friday, February 15th. UBS Group set a $170.00 price objective on Iqvia and gave the company a “buy” rating in a report on Friday, February 15th. Argus raised their price objective on Iqvia from $140.00 to $160.00 and gave the company a “buy” rating in a report on Monday, February 25th. They noted that the move was a valuation call. TheStreet lowered Iqvia from a “b” rating to a “c+” rating in a report on Wednesday, May 1st. Finally, Zacks Investment Research upgraded Iqvia from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. Iqvia currently has a consensus rating of “Buy” and a consensus target price of $146.88.

In related news, insider W Richard Staub sold 27,025 shares of the business’s stock in a transaction dated Wednesday, February 20th. The shares were sold at an average price of $140.54, for a total value of $3,798,093.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael J. Evanisko sold 1,193 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $144.95, for a total transaction of $172,925.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,214,778 shares of company stock worth $593,327,768. 6.00% of the stock is owned by insiders.

NYSE IQV opened at $134.71 on Tuesday. Iqvia Holdings Inc has a 52 week low of $97.64 and a 52 week high of $146.10. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.14 and a current ratio of 1.14. The firm has a market cap of $26.37 billion, a PE ratio of 26.31, a P/E/G ratio of 1.62 and a beta of 0.80.

Iqvia (NYSE:IQV) last posted its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.53 EPS for the quarter, topping the consensus estimate of $1.41 by $0.12. The business had revenue of $2.68 billion for the quarter, compared to analyst estimates of $2.67 billion. Iqvia had a return on equity of 15.08% and a net margin of 2.35%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.34 EPS. Sell-side analysts expect that Iqvia Holdings Inc will post 5.88 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2019/05/21/iqvia-holdings-inc-iqv-shares-sold-by-kendall-capital-management.html.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.